basically needs 1 think to be re-rated and that is for a big pharma to come in and fund further trials.
the single biggest factor between the 'have' and 'have nots' is funding. without a backer, you have dilution.
i'm sure management would be in discussions with a number of pharmas given recent results will have gained the intention of these groups
basically needs 1 think to be re-rated and that is for a big...
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
